tiprankstipranks
Exicure Inc (XCUR)
NASDAQ:XCUR

Exicure (XCUR) AI Stock Analysis

Compare
975 Followers

Top Page

XC

Exicure

(NASDAQ:XCUR)

57Neutral
Exicure's overall stock score is influenced by its challenging financial performance with persistent losses and heavy reliance on external financing, which are major concerns. However, positive technical indicators and significant recent corporate events, like the $8.7 million equity financing, offer some optimism. Despite the negative P/E ratio, the stock's technical stability and potential strategic benefits from the recent financing contribute positively to its score.

Exicure (XCUR) vs. S&P 500 (SPY)

Exicure Business Overview & Revenue Model

Company DescriptionExicure (XCUR) is a biotechnology company focused on developing innovative therapeutics based on its proprietary spherical nucleic acid (SNA) technology platform. Operating in the pharmaceutical and biotechnology sectors, Exicure aims to address unmet medical needs through the development of gene regulatory and immuno-oncology therapeutics. The company's core products are designed to leverage the unique properties of SNA to enhance target engagement and improve therapeutic outcomes.
How the Company Makes MoneyExicure makes money primarily through the development and commercialization of its proprietary therapies derived from its spherical nucleic acid (SNA) platform. Revenue streams include research and development collaborations with pharmaceutical companies, licensing agreements, and potential milestone payments and royalties from partnered programs. Significant partnerships play a crucial role in Exicure's earnings, as they provide funding and resources to advance clinical trials and bring therapies to market. Additionally, Exicure may generate revenue from the successful commercialization of its own pipeline products, pending regulatory approvals.

Exicure Financial Statement Overview

Summary
Exicure faces significant financial challenges, with persistent losses and a heavy reliance on external financing. Although there are signs of improved equity and gross profit margins, the company's financial position remains precarious due to ongoing operational inefficiencies and liquidity issues. Future growth will depend on the ability to stabilize revenues and manage costs effectively while reducing dependency on debt financing.
Income Statement
45
Neutral
Exicure's income statement reveals a challenging financial position characterized by consistent net losses and negative EBIT margins. Despite a significant revenue increase in 2022, the company experienced a steep decline in 2023, with revenue dropping to zero. The gross profit margin turned positive in 2024, but net profit remains deeply negative, indicating ongoing financial struggles and inefficiencies in managing expenses.
Balance Sheet
60
Neutral
The balance sheet shows moderate stability with a positive equity position and a manageable debt-to-equity ratio. The equity ratio indicates a decent capitalization level, although the company has a history of fluctuating liabilities, which could pose future risks. The increasing equity in 2024 suggests improved financial health, but the presence of significant liabilities requires careful monitoring.
Cash Flow
50
Neutral
Exicure's cash flow statement reflects negative free cash flows, primarily driven by substantial operating cash outflows. While financing activities have provided liquidity, the reliance on external funding is evident. The operating cash flow to net income ratio suggests operational inefficiencies, and the free cash flow growth rate has been volatile, indicating potential liquidity challenges.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
500.00K0.0028.83M-483.00K16.61M
Gross Profit
500.00K-1.42M26.97M-2.26M-15.48M
EBIT
-12.23M-15.00M-1.83M-62.55M-25.44M
EBITDA
-8.85M-15.54M78.00K-60.63M-22.65M
Net Income Common Stockholders
-9.70M-16.91M-2.58M-64.10M-24.67M
Balance SheetCash, Cash Equivalents and Short-Term Investments
12.51M816.00K8.58M39.14M82.08M
Total Assets
15.06M11.58M23.33M64.87M100.44M
Total Debt
5.21M6.67M7.31M14.74M24.77M
Net Debt
-7.29M5.85M-1.27M-19.91M-8.49M
Total Liabilities
8.28M8.55M8.41M53.64M38.94M
Stockholders Equity
6.77M3.03M14.92M11.23M61.51M
Cash FlowFree Cash Flow
-2.91M-10.36M-35.67M-35.79M-42.44M
Operating Cash Flow
-2.91M-10.36M-35.66M-34.82M-39.27M
Investing Cash Flow
0.00-1.08M4.70M43.09M10.14M
Financing Cash Flow
13.40M3.67M-3.10M1.12M15.13M

Exicure Technical Analysis

Technical Analysis Sentiment
Positive
Last Price13.20
Price Trends
50DMA
11.22
Positive
100DMA
12.56
Positive
200DMA
7.42
Positive
Market Momentum
MACD
0.79
Negative
RSI
54.93
Neutral
STOCH
32.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XCUR, the sentiment is Positive. The current price of 13.2 is above the 20-day moving average (MA) of 12.61, above the 50-day MA of 11.22, and above the 200-day MA of 7.42, indicating a bullish trend. The MACD of 0.79 indicates Negative momentum. The RSI at 54.93 is Neutral, neither overbought nor oversold. The STOCH value of 32.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XCUR.

Exicure Risk Analysis

Exicure disclosed 22 risk factors in its most recent earnings report. Exicure reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Exicure Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$84.28M-197.92%76.04%
55
Neutral
$35.12B-414.62%22.97%38.54%
49
Neutral
$4.80B-93.03%-10.48%-18.79%
48
Neutral
$6.86B1.11-50.22%2.47%16.71%1.53%
48
Neutral
$10.94B-28.77%-52.75%25.00%
47
Neutral
$1.68B-600.68%-98.62%-86.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XCUR
Exicure
12.30
9.50
339.29%
ALNY
Alnylam Pharma
266.83
116.00
76.91%
ARWR
Arrowhead Pharmaceuticals
12.69
-13.79
-52.08%
IONS
Ionis Pharmaceuticals
28.71
-15.07
-34.42%
MRNA
Moderna
27.72
-73.49
-72.61%

Exicure Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Exicure Secures $8.7 Million in Stock Purchase Deal
Positive
Jan 6, 2025

Exicure has received $8.7 million following the successful closing of a Common Stock Purchase Agreement with HiTron Systems Inc. This financial development is significant for stakeholders as it marks a substantial capital influx, which may impact the company’s operations and strategic positioning in its industry.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.